Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS' kidney rejection drug

The US FDA has approved Bristol-Myers Squibb’s Nulojix to prevent acute rejection in adult patients who have had a kidney transplant

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's (BMS) Nulojix (belatacept), a selective T-cell costimulation blocker, to prevent acute rejection in adult patients who have had a kidney transplant.

The drug is approved for use with other immunosuppressants specifically basiliximab, mycophenolate mofetil and corticosteroids.

"Nulojix is a new option for kidney transplant patients," said Dr Edward Cox, director of office of antimicrobial products in the FDA's Center for Drug Evaluation and Research. 

"This new medication used in combination with other immunosuppressants helps control the immune system and prevents organ rejection in patients receiving kidney transplants."

Results from two controlled Phase III, open-label, randomised, multicentre studies that included more than 1,200 patients and compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine, demonstrated that the recommended Nulojix regimen is safe and effective for the prevention of acute organ rejection.

Nulojix carries a Boxed Warning for an increased risk of developing post-transplant lymphoproliferative disorder (PTLD), a type of cancer where white blood cells grow out of control after an organ transplant. Transplant patients who have never been exposed to Epstein-Barr virus (EBV) have a higher risk of developing PTLD.

Several immunosuppressants, including Nulojix, also carry another Boxed Warning covering the increased risk of serious infections and other cancers.

16th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics